ALS Therapy Development Institute
  • HOME
  • RESEARCH CENTER
  • ALS COMMUNITY
  • SUPPORT US
  • ABOUT US
  • CRO SERVICES
  • Strategy
  • Pipeline
  • Our Partners
  • Clinical Trials
  • Topics Search
Donate Login Register

Topics

  • Aa
    Items: 3
  • Bb
    Items: 0
  • Cc
    Items: 4
  • Dd
    Items: 2
  • Ee
    Items: 0
  • Ff
    Items: 0
  • Gg
    Items: 0
  • Hh
    Items: 1
  • Ii
    Items: 2
  • Jj
    Items: 0
  • Kk
    Items: 0
  • Ll
    Items: 1
  • Mm
    Items: 2
  • Nn
    Items: 1
  • Oo
    Items: 0
  • Pp
    Items: 0
  • Qq
    Items: 0
  • Rr
    Items: 3
  • Ss
    Items: 2
  • Tt
    Items: 14
  • Uu
    Items: 0
  • Vv
    Items: 1
  • Ww
    Items: 1
  • Xx
    Items: 0
  • Yy
    Items: 0
  • Zz
    Items: 0
  • NP001 - Small Molecule - Last Updated: 1/7/2013
    NP001 may lower the levels of activated cytotoxic macrophages in people with ALS reducing inflammation and further injury to the motor nerves.

Find this useful?
Help us fund more science:

Donate Now

Hot Topics in Research

  • A pain reliever for pALS?
  • The DPS: helping PALS breathe better?
  • An early treatment for ALS?
  • What's next after dex?
  • Could MRI get PALS into trials sooner?
  • Neuralstem:safe & tolerable?
  • Exercise: good for PALS?
  • Why is creating ALS drugs so hard?

Follow Us

Monthly Newsletter

Subscribe

Support Us

  • Donate Now
  • Why Support Us
  • How To Support
  • News & Media

What is ALS?

  • What Is ALS?

About ALS TDI

  • About Us
  • Our History
  • Our Team

Upcoming Events

  • 05/18 ALS Bike Trek MN
  • 05/18 Jon Soderberg ALS Benefit
  • 05/20 Pat Grange ALS Open

© 2013 ALS TDI

  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • SecurityMetrics for PCI Compliance, QSA, IDS, Penetration Testing, Forensics, and Vulnerability Assessment
ALS TDI is a 501(c)(3) registered nonprofit organization.